Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide
- 1 February 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (3) , 1580-1586
Abstract
Immunization of amyloid precursor protein transgenic mice with fibrillar β-amyloid (Aβ) prevents Alzheimer’s disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Aβ, containing the B and T cell self epitopes of Aβ, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6% of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Aβ Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Aβ immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Aβ in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-binding peptide (PADRE). Importantly, the PADRE-Aβ1–15 sequence lacks the T cell epitope of Aβ. Immunization of BALB/c mice with the PADRE-Aβ1–15 epitope vaccine produced high titers of anti-Aβ Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Aβ peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.Keywords
This publication has 61 references indexed in Scilit:
- Anti‐Aβ: The good, the bad, and the unforeseenJournal of Neuroscience Research, 2003
- Detangling Alzheimer's DiseaseScience of Aging Knowledge Environment, 2003
- Importance of IgG2c isotype in the immune response to β-amyloid in amyloid precursor protein/transgenic miceNeuroscience Letters, 2003
- Cerebral Hemorrhage After Passive Anti-Aβ ImmunotherapyScience, 2002
- A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk MelanomaJournal of Immunotherapy, 1999
- Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivoVaccine, 1997
- Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptidesImmunity, 1994
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992
- Lymphokine Control of In Vivo Immunoglobulin Isotype SelectionAnnual Review of Immunology, 1990
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989